Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The success of NHS England’s Innovative Medicines Fund will depend on its operational details

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout


  1. NICE & NHS England. (2022).

  2. Lievens, Y. et al. Lancet Oncol. 20, e112–e123 (2019).

    Article  PubMed  Google Scholar 

  3. NICE. (2009).

  4. NICE. (2022).

  5. Nguyen, V. T. et al. BMC Med. 19, 279 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Hernán, M. A. et al. J. Clin. Epidemiol. 79, 70–75 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Naci, H. et al. Br. Med. J. 366, l5221 (2019).

    Article  Google Scholar 

  8. James, N. D. et al. BJU Int. 103, 464–469 (2009).

    Article  CAS  PubMed  Google Scholar 

  9. Aggarwal, A. et al. Ann. Oncol. 28, 1738–1750 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. NHS England. (2022).

Download references


We thank A. Miners, R. Grieve and J. Cairns for helpful comments on earlier versions of this article.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Aris Angelis.

Ethics declarations

Competing interests

A. Angelis was a 2021–2022 National Institute for Health and Care Excellence (NICE) Scholar; has received research grants from Novartis and Krystal Biotech and consultancy fees from the Department of Health and Social Care and the European Commission; and shares ownership in a health tech company developing software tools for decision-making. A.B. has acted as consultant to various commercial companies that have products funded through the NHS.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Angelis, A., Aggarwal, A. & Briggs, A. The success of NHS England’s Innovative Medicines Fund will depend on its operational details. Nat Med 29, 289–291 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research